CYP7A1 and metabolic dysfunction-associated steatotic liver disease: HDCA intervention has been found to alleviate human non-alcoholic fatty liver disease (NAFLD) by activating the alternative pathway centered on CYP7B1, inhibiting the classical pathway centered on CYP7A1, altering the bile acid synthesis pathway in the liver [13].